ON DEMAND
Redefining Precision Oncology with MSK-ACCESS® powered with SOPHiA DDM™
Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers. In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay.
Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.
In this session you will:
- Discover how the SOPHiA GENETICS decentralised approach and advanced analytics enables scalable, robust, and reproducible liquid biopsy testing, through its decentralized approach, supported by large-scale evidence generation studies across local deployments.
- Gain insights into the clinical impact and utility of adopting MSK-ACCESS® powered with SOPHiA DDM™, and how it improves access and outcomes for cancer patients.
- Explore how decentralized testing strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.
Date it was presented - 12th November 2025